Fosamax esophageal side effects more serious than seen in clinical trials -- Merck letter to doctors.
MERCK FOSAMAX ESOPHAGEAL SIDE EFFECTS MORE SEVERE than previously seen in clinical trials, the company told health care professionals in a March 18 letter. The letter states that "since market introduction of the product, some [esophageal] side effects have been of greater severity than we observed in our controlled clinical trials. It is clear from the case reports...that Fosamax can be irritating to the esophagus but that careful adherence to the dosing instructions can reduce the potential for these side effects." Merck sent the letter to 150,000 physicians; the company sent another 50,000 letters to pharmacists March 25.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth